January 2020

CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019

January 20, 2020

Evidence-Based Oncology

Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies.

CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapy

January 20, 2020

Evidence-Based Oncology

A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.

ASH 2019 Interview: Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML

January 21, 2020

Evidence-Based Oncology

The abstract presented by Kwanza Price, MPH, of Jazz Pharmaceuticals, gathered data from August 1, 2017, and February 28, 2019, capturing the first 19 months of claims data after the biotech received FDA approval for its fixed-dose therapy for 2 types of poor-prognosis acute myeloid leukemia.

AJMCtv Interviews: ASH19 Edition

January 22, 2020

Evidence-Based Oncology

Interviews with researchers and opinion leaders that took place during the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, December 7-10, 2019.